Barbara Lopez Kunz is leading the transformation of DIA through developing and implementing a strategy that focuses on driving innovation to improve the health of people worldwide. She is responsible for the leadership and oversight of DIA global operations and is accountable to the DIA Board of Directors.
Barbara has held executive positions in for-profit and non-profit organizations. Prior to joining DIA, she served as President of Health and Life Sciences at Battelle, one of the world’s largest, most respected R&D organizations, delivering $6.5 billion of R&D across more than 100 global locations. She has also served as Senior VP/GM for Thermo Fisher Scientific’s Biosciences Business, building the organization’s breadth and reach through acquisitions & strategic alliances with partners in the biopharmaceutical, diagnostics & academic communities to establish a $1.4 billion portfolio. She also led ICI/Uniqema’s Latin America regional business, guiding it to growth during one of the most volatile periods in the region’s history by establishing regional entities to take advantage of local trading opportunities, greatly improving cost effectiveness throughout the region. Barbara started her career as a scientist and holds 14 patents.
Barbara has held various Board positions at Ohio State University Wexner Medical Center, BioOhio, International Scientific Standards (a joint venture in South Korea that enables the delivery of medical products to patients), and medical device companies, Levitronix and POCARED. She has actively supported children’s health, serving on the inaugural board of the Childhood League School, addressing needs of developmentally challenged children in central Ohio, and as a trustee of Nationwide Children’s Hospital Research Institute. Barbara holds an MS in Polymer Science from the University of Akron, a BS from Thiel College, and qualified in INSEAD’s International Executive program.